Curexsys GmbH, Göttingen, Germany.
PhD Biomedical and Biological Sciences Program, School of Medicine and Health Sciences, Universidad del Rosario, Bogotá, Colombia.
Sci Rep. 2024 Oct 15;14(1):24098. doi: 10.1038/s41598-024-75956-3.
Induced pluripotent stem cell (iPSC)-derived mesenchymal stromal cells (iMSCs) offer a promising alternative to primary mesenchymal stromal cells (MSCs) and their derivatives, particularly extracellular vesicles (EVs), for use in advanced therapy medicinal products. In this study we evaluated the immunomodulatory and regenerative potential of iMSCs as well as iMSC-EVs, alongside primary human umbilical cord-derived mesenchymal stromal cells (hUCMSCs). Our findings demonstrate that iMSCs exhibit comparable abilities to hUCMSCs in regulating lymphocyte proliferation and inducing an anti-inflammatory phenotype in monocytes. We also observed decreased TNFα levels and increased IL-10 induction, indicating a potential mechanism for their immunomodulatory effects. Furthermore, iMSC-EVs also showed effective immunomodulation by inhibiting T cell proliferation and inducing macrophage polarization similar to their parental cells. Additionally, iMSC-EVs exhibited pro-regenerative potential akin to hUCMSC-EVs in in vitro scratch assays. Notably, priming iMSCs with pro-inflammatory cytokines significantly enhanced the immunomodulatory potential of iMSC-EVs. These results underscore the considerable promise of iMSCs and iMSCs-EVs as an alternate source for MSC-derived therapeutics, given their potent immunomodulatory and regenerative properties.
诱导多能干细胞(iPSC)衍生的间充质基质细胞(iMSC)为先进治疗药物产品提供了一种有前途的替代原代间充质基质细胞(MSC)及其衍生物,特别是细胞外囊泡(EVs)的选择。在这项研究中,我们评估了 iMSC 及其 EVs 与原代人脐带衍生的间充质基质细胞(hUCMSC)的免疫调节和再生潜力。我们的研究结果表明,iMSC 在调节淋巴细胞增殖和诱导单核细胞抗炎表型方面与 hUCMSC 具有相当的能力。我们还观察到 TNFα 水平降低和 IL-10 诱导增加,表明其免疫调节作用的潜在机制。此外,iMSC-EVs 通过抑制 T 细胞增殖和诱导巨噬细胞极化也表现出有效的免疫调节作用,类似于其亲本细胞。此外,iMSC-EVs 在体外划痕实验中表现出类似于 hUCMSC-EVs 的促再生潜力。值得注意的是,用促炎细胞因子预先刺激 iMSC 可显著增强 iMSC-EVs 的免疫调节潜力。这些结果强调了 iMSC 和 iMSC-EVs 作为 MSC 衍生治疗药物替代来源的巨大潜力,因为它们具有强大的免疫调节和再生特性。